CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

About this update from Cns Pharmaceuticals, Inc.

[{"type":"text","content":"In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM)","length":172,"tagName":"p"},{"type":"text","content":"HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sandra Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals, will present at the Lenox Hill Hospital, Department of Neurosurgery's Brain Tumor Biotech Summit being held on June 5, 2025 in New York, NY.","length":531,"tagName":"p"},{"type":"text","content":"Details of the presentation are as follows:","length":43,"tagName":"p"},{"type":"text","content":"Title: The Future and Promise of TPI 287- A Brain Penetrating Taxane with Documented Evidence of Efficacy Against GlioblastomaDate and Time: Thursday, June 5, 2025 at 9:30 AM ET","length":178,"tagName":"p"},{"type":"text","content":"As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier (BBB), TPI 287's clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab (Avastin®), the efficacy data included 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients.","length":739,"tagName":"p"},{"type":"text","content":"TPI 287 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.","length":188,"tagName":"p"},{"type":"text","content":"The 2025 Brain Tumor Biotech Summit brings together innovators in neuroscience and oncology with investors in the field of biotechnology and healthcare life science. The Conference'...

More updates from Cns Pharmaceuticals, Inc.